Halozyme Therapeutics Inc (HALO)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 363,821 | 83,808 | 169,798 | 196,953 | 151,047 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $363,821K
= 0.00
Based on the provided data, the debt-to-equity ratio of Halozyme Therapeutics Inc has been consistently at 0.00 for the years 2020, 2021, 2022, 2023, and 2024. This indicates that the company has not utilized any debt to finance its operations during that period, resulting in a debt-free capital structure. A debt-to-equity ratio of 0.00 signifies that the company's total liabilities are equal to zero or significantly lower than its total equity, indicating low financial risk and a potentially strong financial position with a higher proportion of equity financing. Investors and stakeholders may view this ratio favorably as it suggests that the company has not taken on excessive debt obligations, leading to lower interest expenses and potentially higher profitability.
Peer comparison
Dec 31, 2024